Microwave ablation of primary and secondary liver tumours: <i>ex vivo</i>, <i>in vivo</i>, and clinical characterisation

Abstract

For the selected MW ablation device, ex vivo data on bovine liver was more predictive of the actual clinical performance on liver malignancies than an in vivo porcine model. Equivalent MW treatments yielded a significantly different response for HCC and metastases at higher deposited energy, suggesting that outcomes are not only device-specific but must also be characterised on a tissue-by-tissue basis.